Latest One Wales decisions
- 14/02/2024
- Bendamustine and rituximab for indolent lymphomas (OW08)
-
-
-
Last review date: February 2024
- 14/02/2024
- Rituximab for interstitial lung disease (OW13)
-
-
-
Last review date: February 2024
- 26/07/2021
- Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04)
-
-
-
Last review date: November 2023
- 26/07/2021
- Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06)
-
-
-
Last review date: September 2023
- 24/05/2022
- Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15)
-
-
-
Last review date: August 2023
- 24/05/2022
- Rituximab for pemphigus and pemphigoid (OW10)
-
-
-
Last review date: July 2023
- 12/04/2022
- Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18)
-
-
-
Last review date: June 2023
- 15/02/2023
- Denosumab (Prolia®) for osteoporosis in men (OW07)
-
-
-
Last review date: December 2022